Enliven Therapeutics (ELVN) CMO sells 45,000 shares after option exercise

Rhea-AI Filing Summary

Enliven Therapeutics, Inc.’s Chief Medical Officer Helen Louise Collins exercised stock options and sold shares in a planned transaction. She exercised options for 45,000 shares at $2.48 per share, converting them into 45,000 shares of common stock.

She then sold 45,000 common shares at a weighted average price of $26.1747, with trade prices ranging from $25.76 to $26.695, under a Rule 10b5-1 trading plan adopted on October 19, 2025. After these transactions, she directly held 25,000 shares of common stock and 221,268 option shares, all of which were fully vested and exercisable as of the transaction date.

Insider Trade Summary

Net Seller: 45,000 shares ($1,177,862)

Net Sell 3 txns

Insider Collins Helen Louise

Role CHIEF MEDICAL OFFICER

Sold 45,000 shs ($1.18M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	45,000	$0.00	--
Exercise	Common Stock	45,000	$2.48	$112K
Sale	Common Stock	45,000	$26.1747	$1.18M

Holdings After Transaction: Stock Option (right to buy) — 221,268 shares (Direct); Common Stock — 70,000 shares (Direct)

Footnotes (1)

1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. This transaction was executed in multiple trades at prices ranging from $25.76 to $26.695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Collins Helen Louise

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		M(1)		45,000	A	$2.48	70,000	D
Common Stock	02/17/2026		S(1)		45,000	D	$26.1747(2)	25,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.48	02/17/2026		M(1)			45,000	(3)	06/17/2031	Common Stock	45,000	$0	221,268	D

Explanation of Responses:

1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.

2. This transaction was executed in multiple trades at prices ranging from $25.76 to $26.695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

	/s/ Ben Hohl, by power of attorney	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Enliven Therapeutics (ELVN) CMO Helen Collins report on this Form 4?

Helen Collins reported exercising 45,000 stock options and selling 45,000 common shares. The transactions converted options into stock and then liquidated those shares, while leaving her with remaining direct holdings in both common stock and vested options.

How many Enliven Therapeutics (ELVN) shares did Helen Collins sell and at what price?

Helen Collins sold 45,000 shares of Enliven Therapeutics common stock. The weighted average sale price was $26.1747 per share, with individual trades executed between $25.76 and $26.695 according to the reported transaction details.

At what price did Helen Collins exercise her Enliven Therapeutics (ELVN) stock options?

She exercised 45,000 stock options at an exercise price of $2.48 per share. These options were fully vested and exercisable on the transaction date, allowing conversion into an equal number of Enliven Therapeutics common shares before the subsequent sale.

Were Helen Collins’ Enliven Therapeutics (ELVN) trades under a Rule 10b5-1 plan?

Yes. The option exercise and related stock sales were carried out under a Rule 10b5-1 trading plan. The plan was adopted on October 19, 2025, indicating the trades were pre-arranged rather than newly opportunistic decisions.

How many Enliven Therapeutics (ELVN) shares does Helen Collins hold after these transactions?

After the reported trades, Helen Collins directly holds 25,000 shares of Enliven Therapeutics common stock. She also holds 221,268 option shares, and all of the shares subject to this option grant are fully vested and exercisable as of the transaction date.